Advanced Biomed Inc.
ADVBDrugs in Pipeline
26
Phase 3 Programs
13
Upcoming Catalysts
3
Next Catalyst
Mar 15, 2026
5wMarket Overview
Stock performance and market intelligence
3 upcoming, 0 past
[18F]PSMA-1007 Phase 3 Results Expected
Primary completion for [18F]PSMA-1007 trial (NCT06122584) in Prostate Cancer
SourceABD-3001 Phase 2 Results Expected
Primary completion for ABD-3001 trial (NCT05601726) in Acute Myeloid Leukemia, Adult
SourceVodobatinib (K0706) capsules Phase 2 Results Expected
Primary completion for Vodobatinib (K0706) capsules trial (NCT02629692) in Healthy (For Part A)
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
[18F]PSMA-1007
Prostate Cancer
Rubidium-82
Coronary Artery Disease
F-18-PSMA-1007
Prostate Cancer
Cethromycin
Pneumonia
SPARC0913
Open Angle Glaucoma
Clarithromycin
Pneumonia
Lutathera
Gastro-enteropancreatic Neuroendocrine Tumor
SPARC0912
Open Angle Glaucoma
SDN-037
Inflammation and Pain Associated With Ocular Surgery
Octreotide LAR
Carcinoid Tumor of the Small Bowel
Brimonidine Tartrate Ophthalmic Suspension
Open Angle Glaucoma
SPARC0921
Spasticity
SPARC1104 modified dose regimen I
Spasticity
Lutetium [177Lu] oxodotreotide/dotatate
Gastroenteropancreatic Neuroendocrine Tumors
Vodobatinib (K0706) capsules
Healthy (For Part A)
ATH008
Palmar-Plantar Erythrodysesthesia Syndrome
PrimePro™/ PrimeMSK™
Autoimmune Diseases
SPARC1103 low dose
Spasticity
SPARC1203
Allergic Rhinitis
[68Ga]-PSMA-R2
Prostate Cancer Metastatic
Acadesine
Leukemia, B-Cell, Chronic
SPARC1310 I
Seasonal Allergic Rhinitis
SPARC1316 Dose 1
Asthma
[177Lu]-NeoB
Neoplasms
SPARC1102 I
Allergic Conjunctivitis
ABD-3001
Acute Myeloid Leukemia, Adult
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
[18F]PSMA-1007 | Phase 3 | Prostate Cancer | - |
Rubidium-82 | Phase 3 | Coronary Artery Disease | - |
F-18-PSMA-1007 | Phase 3 | Prostate Cancer | - |
Cethromycin | Phase 3 | Pneumonia | - |
SPARC0913 | Phase 3 | Open Angle Glaucoma | - |
Clarithromycin | Phase 3 | Pneumonia | - |
Lutathera | Phase 3 | Gastro-enteropancreatic Neuroendocrine Tumor | - |
SPARC0912 | Phase 3 | Open Angle Glaucoma | - |
SDN-037 | Phase 3 | Inflammation and Pain Associated With Ocular Surgery | - |
Octreotide LAR | Phase 3 | Carcinoid Tumor of the Small Bowel | - |
Brimonidine Tartrate Ophthalmic Suspension | Phase 3 | Open Angle Glaucoma | - |
SPARC0921 | Phase 3 | Spasticity | - |
SPARC1104 modified dose regimen I | Phase 3 | Spasticity | - |
Lutetium [177Lu] oxodotreotide/dotatate | Phase 2 | Gastroenteropancreatic Neuroendocrine Tumors | - |
Vodobatinib (K0706) capsules | Phase 2 | Healthy (For Part A) | - |
ATH008 | Phase 2 | Palmar-Plantar Erythrodysesthesia Syndrome | - |
PrimePro™/ PrimeMSK™ | Phase 2 | Autoimmune Diseases | - |
SPARC1103 low dose | Phase 2 | Spasticity | - |
SPARC1203 | Phase 2 | Allergic Rhinitis | - |
[68Ga]-PSMA-R2 | Phase 2 | Prostate Cancer Metastatic | - |
Acadesine | Phase 2 | Leukemia, B-Cell, Chronic | - |
SPARC1310 I | Phase 2 | Seasonal Allergic Rhinitis | - |
SPARC1316 Dose 1 | Phase 2 | Asthma | - |
[177Lu]-NeoB | Phase 2 | Neoplasms | - |
SPARC1102 I | Phase 2 | Allergic Conjunctivitis | - |
ABD-3001 | Phase 2 | Acute Myeloid Leukemia, Adult | - |
Regulatory & News
Approvals, filings, and latest developments